CGRP mAbs Are Effective Long-Term for Migraine Prevention According to 3-Year Longitudinal Study
Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) demonstrated long-term efficacy in preventing migraines, according to a study presented at the 65th Annual Scientific Meeting of the American Headache Society (AHS).
In the 3-year longitudinal study, Electronic Medical Records (EMRs) with migraine frequency data were extracted for 2025 patients from the Cleveland Clinic. Eligible patients had been receiving a CGRP mAb for 6 consecutive months between June 2018 and December 2021. The cohort was 87.5% female, had a mean age of 47 years, and included 1586 individuals with chronic migraine. Researchers assessed monthly migraine days (MMDs) at 1, 2, and 3 years of treatment and characterized participants as being super-responders (MMD reduction of at least 75%), responders (reduction between 26%-74%), or non-responders (reduction of 25% or less).
Over the course of 3 years of treatment, researchers found that CGRP mAbs maintained efficacy with only a minor loss in benefit. Super-responders made up 55.5% of participants after the first year, 53.6% after the second year, and 59.5% after the third year. Responders made up 38.4% of participants after the first year, 37.6% after the second year, and 29.7% after the third year. Non-responders made up 6.2% of participants after the first year, 9.1% of participants after the second year, and 10.8% of participants after the third year.
The CGRP mAbs evaluated in this study included Aimovig (erenumab, Amgen Inc, Thousand Oaks, CA; Novartis AG, Basel, Switzerland), Ajovy (fremanezumab, Teva Pharmaceutical Industries Ltd, Tel Aviv, Israel), and Emgality (Eli Lilly and Company, Indianapolis, IN). The study authors are from the University of Iowa and the VA Center for the Prevention and Treatment of Visual Loss.